Project Grant R01GM160155
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
- This federal Project Grant award of $119,907 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research to dissect the dynamics, functions, and evolution of TNPB, a miniature RNA-guided enzyme. The research aims to enhance the genome-editing efficiency of TNPB and expand its applications beyond DNA cleavage. Specifically, the project seeks to address three key knowledge gaps: (1) the molecular...
- This $314,000 Project Grant was awarded on September 1, 2025 by the National Institute of General Medical Sciences (NIGMS), which administers the Biomedical Research and Research Training program (CFDA 93.859). The grant was awarded to Cellfe, Inc. to optimize their CellFE microfluidic transfection platform for accelerated, scalable same-day sequential gene editing of T cells for allogeneic cell therapies. The project aims to enhance the speed, precision, and scalability of CRISPR-based gene...
- This federal Project Grant award of $1,638,033, provided by the National Institutes of Health (NIH) under the Biomedical Research and Research Training Program (CFDA 93.859), supports the development of a CRISPR-free mammalian recombineering system at the Scripps Research Institute. The project aims to characterize and optimize a bacterial recombinase system for efficiently conducting large-scale DNA insertions, deletions, and substitutions in mammalian cells without inducing cytotoxic...
- The National Institute of General Medical Sciences (NIGMS) awarded a $376,498 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to the University of California, San Diego (UCSD) for a 5-year research program from August 1, 2025 to July 31, 2030. The research will focus on developing new active genetic systems that can function in both germline and somatic cell contexts. This includes exploring the use of CRISPR-based gene drive systems to potentially...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $394,857 to the University of Nebraska to develop a system to protect and concentrate large DNA molecules for genome analysis. The project aims to: Develop an inverted insert to protect DNA during cell lysis. Develop a roadblock to concentrate chromosomal DNA. The goal is to create a method to protect and concentrate large DNA molecules...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $100,000 will support research to develop next-generation clustered regularly interspaced short palindromic repeat (CRISPR) systems for curing inherited diseases. Specifically, the awardee, the University of California, Berkeley, will work to circumvent in vivo delivery challenges with CRISPR-Cas9 by developing miniature RNA-guided genome editors smaller than Cas9 that can be...
- This $408,375 federal Project Grant awarded on August 18, 2025 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to uncover the rules governing the spread of mobile genetic elements (MGEs) in microbes. The project aims to characterize MGE compatibility and how MGEs and microbial chromosomes co-evolve to maintain compatibility, using plasmids in the Agrobacteria/Rhizobia complex as a model...
- This $117,074 Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences program (CFDA 47.049) supports research at Lehigh University to develop biomaterial-guided CRISPR gene editing delivery systems. The key objectives are to: Determine how peptide-based nanoparticle formulation and properties impact CRISPR ribonucleoprotein (RNP) uptake, activity, and functionality. Investigate how material charge and porosity control the temporal action of CRISPR...
- The Project Grant award of $427,079.00, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop DNA-based transistors capable of precisely controlling cellular functions. The research project, titled "DNA Transistors for Cellular Programming," focuses on creating synthetic receptors that can respond to specific DNA sequences, enabling control over cellular activities both externally...
This federal Project Grant award, with a total funding of $522,764, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The grant aims to develop a platform technology based on the PiggyBac (PB) transposase, which facilitates precise DNA insertion into specific genomic sequences with minimal off-target effects. This novel gene integration approach is intended to address the limitations of current genome editing technologies, such as CRISPR, in efficiently delivering large DNA fragments, particularly in non-dividing cells. The project will optimize the PB transposase through directed evolution to enhance its efficiency and specificity, establishing a versatile gene therapy platform for both therapeutic and research applications. The award was granted to the University of Hawaii at Manoa, a leading federal research partner with expertise in areas like astronomy, oceanography, and environmental studies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $522.8k | 9/4/25 |